

North Yorkshire & York Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on the 1st September 2021

Classification of products:

- G** **Green drug** - Can be initiated and prescribed in all care settings **○**- Second line / alternative green drug
- ASR** **Amber Specialist Recommendation drug** - Can be recommended by a specialist for initiation in primary care
- ASI** **Amber Specialist Initiation drug** – Initiated by a specialist and transferred to primary care once the patient stabilised. In some cases there may be a further restriction for use outlined - these will be defined in each case.
- ASC** **Amber Shared Care drug** - These are specialist drugs which must be initiated by the specialist, but with the potential to transfer to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care
- R** **Red drug** - Drugs that should remain under the total responsibility of the specialist. Usually considered as “hospital only” drugs
- BLACK Not Approved** - Drugs that have been considered by the APC or other approved body and are not approved for prescribing within North Yorkshire & York.
- GREY Not Reviewed** - Drugs that haven't been reviewed by the APC yet. This usually means that no application has been received or that an application is in progress. These drugs are not normally considered appropriate for prescribing in North Yorkshire & York.

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
1) Requests deferred from previous meetings				
TA694: Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia			✓	Decision deferred to confirm with NICE and local lipid specialists in place therapy in those whose dose of statin cannot be increased to usually max recommended dose.
2) New Requests				
Grass Pollen Extract (Grazax®)			✓	Decision deferred to next APC meeting to confirm risk of anaphylaxis when administered at home.
Mycophenolate for autoimmune hepatitis	✓ ASC			Decision: approved as 2 nd line alternative to azathioprine. Noted in current Leeds and Hull SCGs for this indication.
Infliximab for Pityriasis Rubra Pilaris	✓ R			Decision: approved.
3) New formulations & extensions to use				
Nil this month				
5) Products considered by NICE				
TA720: Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
TA721: Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer	 BLACK			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA722: Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement	 			The formulary will reflect the TAG – NHS England is the responsible commissioner.
6) Appeals against earlier decisions by the APC				
None				
7) Miscellaneous formulary decisions by the APC				
Nil this month.				

The following guidelines were presented to and approved at the September 2021 meeting of the APC:

- Dry Eyes Guideline

The following shared care guidelines were presented to and approved at the September 2021 meeting of the APC:

- Nil this month

Other documents presented to and approved at the September 2021 meeting of the APC:

- Gastrointestinal Formulary - the first BNF chapter to be aligned across North Yorkshire and York.